[Nfbf-l] Research to begin!

[Kirk]

I found this  exciting to read for our seniors with MD! KH
Clinical Trial for Wet AMD Gene Therapy to Begin in December 2010
Oxford BioMedica has received FDA authorization to launch a clinical trial 
of its RetinoStat® gene therapy for the treatment of wet age-related macular 
degeneration. Eighteen people will be enrolled in the Phase I/II trial to be 
conducted at The Wilmer Eye Institute at Johns Hopkins.

Emerging Wet AMD Treatment May Require Fewer Injections
Two Phase III clinical studies have shown that injections of VEGF Trap every 
eight weeks were as effective as injections of Lucentis® every four weeks in 
the treatment of wet age-related macular degeneration.

Kirk Harmon
President & CEO
Florida Disabled Citizens
for Progress
P.O.Box 61794
Jacksonville, FL 32236
PH(904) 783-9896
Cell: (407) 473-2176
DAV/BVA
Life Member

" TURNING HOPE INTO REALITY"